Novo Nordisk (NVO) stock surged over 6% after FDA approval of Wegovy for MASH treatment. Ozempic now available to cash-paying U.S. customers for $499/month. Stock down 40% YTD due to competition with Eli Lilly. FDA approval expands NVO’s clinical footprint and revenue stream. GLP-1 market dominance and affordability focus increase investor confidence.

Analysts see NVO stock decline as a buying opportunity. NovoCare program boosts demand for Wegovy. Management committed to advancing CagriSema and cagrilintide monotherapy. EVOKE trial in Alzheimer’s shows strategic expansion. TD Cowen remains bullish on NVO stock, no price target shared. Consensus rating “Moderate Buy” with potential 30% upside.

Investors should consider buying NVO stock at current levels. Other Wall Street firms bullish on NVO too. Mean target price of $71 suggests 30% upside potential. All information in this article is for informational purposes only.

Read more at Yahoo Finance: Should You Buy the Pop in Novo Nordisk Stock?